Translate page

The importance of BCR-ABL kinase domain
mutation analysis in CML

Susan Branford, University of Adelaide, Australia

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.


vep branford mutationanalysis


Issues covered

  • Mutations as a mechanism of imatinib resistance
  • Why mutations arise
  • When to test for mutations
  • Therapeutic options in the presence of mutations


Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib